Sarepta bows to FDA pressure, pulls Duchenne therapy from market
The Boston Business Journal's Power 50, "The Movement Makers," focuses on those in the Boston-area business community who demonstrate the most influence on making both their company and the region a better place for everyone in it.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Journals
an hour ago
- Business Journals
Canadian pub sets opening date for first Houston-area location in The Woodlands (RENDERINGS)
Local Public Eatery, a Canadian pub-like restaurant, will open its first Houston-area location in The Woodlands Aug. 21. It will be the brand's second location in Texas following one in Dallas, which opened in 2024.
Yahoo
2 hours ago
- Yahoo
Stifel Keeps Buy Rating on Compass Therapeutics (CMPX)
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 10 Best Performing Penny Stocks So Far in 2025. On July 14, Stifel reiterated its 'Buy' rating for Compass Therapeutics, Inc. (NASDAQ:CMPX) with a price target of $11. This decision came after investor meetings with the company's management. According to the research firm, the extended timeline for overall survival event accrual in the Phase 2/3 COMPANION-002 trial is a good thing. The trial is testing paclitaxel with or without tovecimig in patients with second-line biliary tract cancer. A biopharmacist holding a magnifying glass up against a microscope lens, studying a biological sample. Compass Therapeutics, Inc. (NASDAQ:CMPX) now expects to share the topline data in the fourth quarter of 2025. This means patients will be followed up for more than 19 months on average. Stifel noted that this is important because in this disease, the overall survival of the control arm rarely goes beyond 6 months. Besides the COMPANION-002 trial, Stiefl analysts believe upcoming data disclosures for two other compounds in the second half of 2025 could potentially prove to be important catalysts for Compass Therapeutics, Inc. (NASDAQ:CMPX). These include Phase 1 dose-escalation data for CTX-8371, a PD-1xPD-L1 bispecific antibody, and preclinical data for CTX-10726, a PD-1xVEGF-A bispecific antibody. Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. The company focuses on the relationship between angiogenesis, the immune system, and tumor growth. While we acknowledge the potential of CMPX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Proteomics Market to Expand Rapidly, with 13% CAGR forecast Through 2030
"Advances in proteomics technologies are driving growth in precision medicine, with rising demand for early diagnostics, personalized therapies, and deeper insights into disease mechanisms." BOSTON, July 25, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Proteomics: Technologies and Global Markets" was valued at $27.6 billion in 2024 and is projected to grow from $31.0 billion in 2025 to $57.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.0% from 2025 to 2030. The report offers a detailed analysis of the global market for proteomic technologies, segmented by product type (instruments and software, consumables), platform (mass spectrometry, biochip), application (drug discovery and development, research, diagnostics, applied proteomics), and region (North America, Europe, Asia-Pacific, and Rest of the World). Protein structural analysis and protein-expression products are outside the scope of the report. The study discusses market trends, challenges, and emerging technologies, while also examining the competitive landscape and the market shares of leading vendors. It includes a section on ESG trends and provides company profiles that include insights into financials, product portfolios, and recent advances. This analysis serves as a valuable resource for understanding strategic opportunities and market dynamics in the evolving proteomics sector. This report is particularly relevant today due to the growing demand for innovative and personalized therapies, which is driving advances in proteomic technologies. Increased investments in R&D are accelerating the discovery of new biomarkers, which are crucial for early and accurate diagnosis of diseases. These trends underscore the importance of proteomics in shaping the future of precision medicine and improving healthcare outcomes. The factors driving the market's growth include: Increasing Investments in R&D: Governments, biotech firms, and academic institutions are increasing funding in proteomics research to drive innovation in diagnostics, drug discovery, and therapeutic development. Transition Towards Personalized Medicine: Proteomics enables the identification of protein biomarkers that support tailored treatments based on individual biological profiles, making it a cornerstone in the shift toward personalized healthcare. Aging Population and Prevalence of Chronic Diseases: As the global population ages, chronic conditions like cancer and cardiovascular diseases are becoming more common, increasing the demand for proteomics tools that aid in early detection and targeted treatment. Emerging Technologies: Advances such as high-resolution mass spectrometry, AI-driven data analysis, and single-cell proteomics are accelerating research making it more precise, and cost-effective, thereby expanding the scope and impact of proteomics. Request a sample copy of the global market for proteomic technologies report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $27.6 billion Market size forecast $57.2 billion Growth rate CAGR of 13.0% from 2025 to 2030 Segments covered Platform, Application, Product Type and Region Regions covered North America, Europe, Asia-Pacific and the Rest of the World (RoW) Countries covered U.S., Canada, Mexico, Germany, the U.K., Italy, France, Spain, Japan, China, India, South Korea, Rest of Asia-Pacific, and Rest of Europe Market drivers Increasing investments in R&D. Transition towards personalized medicine. Aging population and growing prevalence of chronic diseases. Emerging technologies. Interesting facts: Advances in Technology: The market has seen notable progress in mass spectrometry, particularly with improvements in software and automation that streamline essential processes like sample preparation. Innovation from Emerging Companies: Start-up companies such as Nautilus and SomaLogic have introduced innovative platforms that are expected to reshape the market's future. Emerging startup: Alamar Biosciences Nautilus Biotechnology Pixelgen Technologies Syncell Inc. Sengenics The report addresses the following questions: What is the projected size and growth rate of the market?- The global proteomics market was valued at $27.6 billion in 2024 and is expected to grow at a CAGR of 13% to reach $57.2 billion by the end of 2030. Which factors are driving the growth of the market?- The global market of proteomic technologies is growing due to the rising aging population and growing prevalence of chronic diseases, increasing investments in R&D and in the biotechnology sector, and rising demand for personalized medicine. Which market segments are covered in the report?- The global market for proteomic technologies is segmented based on platform, product type, application, and region. Which platform type will be dominant through 2030?- The mass spectrometry segment will be dominant through 2030. Which region has the largest market share?- North America holds the largest share of the market. Market Leaders include: AGILENT TECHNOLOGIES INC. ARRAYIT CORP. BIO-RAD LABORATORIES INC. BIO-TECHNE BRUKER CREATIVE PROTEOMICS DANAHER CORP. JEOL LTD. MERCK KGAA PROMEGA CORP. REVVITY SHIMADZU CORP. STANDARD BIOTOOLS THERMO FISHER SCIENTIFIC INC. WATERS CORP. Related reports: Single-Cell Genomics and Proteomics: Emerging Technologies and Markets: This report reviews the single-cell genomics and proteomics market, highlighting its current landscape and future potential. It examines key market drivers, challenges, and opportunities, and segments the market by product type (genomics, epigenomics, transcriptomics), application areas (oncology and immunology), end users (academic institutions and biotech companies), and regions (North America, Europe, Asia-Pacific, and the Rest of the World). It also includes profiles of major companies, covering their business segments, financials, product offerings, and recent developments. Global Multiomics Market: This report provides a detailed analysis of the global multiomics market, focusing on products, platforms, applications, end-users, and regions. It explores market trends and forecasts, along with insights into major players and geographic opportunities. The report also includes strategic tools like PESTEL and ESG analysis, competitive assessments, and recommendations to help companies plan effectively. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC
